+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.

Age: 18Years +All GendersPhase 3
838 locations
S

Actively Recruiting

Researchers are evaluating the effects of intravenous ferric carboxymaltose FCM compared with a placebo on death risk, heart failure events, NT-proBNP levels, and quality of life in patients who recently had an acute myocardial infarction AMI and have iron deficiency. This phase 4, multicenter, randomized, double-blind, placebo-controlled clinical trial aims to assess these outcomes over a follow-up period ranging from 8 to 36 months. Participants are randomly assigned to receive either an intravenous 15-minute infusion of 1000 mg FCM diluted in saline or a placebo infusion of saline alone. The first dose is given on the day of randomization, with follow-up visits at 4, 8, 12, 18, 24, and 30 months to reassess participants and possibly repeat treatment if safety criteria are met. During the study, participants undergo evaluations including monitoring of death rates, heart failure events such as unplanned hospitalizations or emergency visits, changes in NT-proBNP concentration, and quality of life measured by the EQ-5D questionnaire. Safety and treatment effects are tracked throughout the follow-up period, which can last up to 36 months from the start of participation.

Age: 18Years - 90YearsAll GendersPhase 4
43 locations
O

Actively Recruiting

This research focuses on participants who have completed a previous Novartis-sponsored study involving remibrutinib, a drug used in dermatological or allergology conditions. It aims to provide continued access to remibrutinib treatment and monitor long-term safety for up to three years, specifically for those benefiting from the treatment and unable to access it outside clinical trials. Participants will receive remibrutinib tablets at the dose and schedule they last followed in their earlier study. There is no screening period after consent and enrollment at the study site, treatment begins immediately. Participants will return to the study center at least every 16 weeks to receive their medication supply but may come back sooner if needed. Treatment can continue up to three years or until certain conditions such as loss of benefit, withdrawal, pregnancy, or other reasons arise. During the study, participants will have regular visits for medication resupply and monitoring. Researchers will track adverse events and serious adverse events throughout the study duration, approximately seven years, to assess long-term safety. Participation involves ongoing evaluation by the investigator to ensure benefits outweigh risks, with continuous access to treatment under medical supervision.

Age: 12Years - 100YearsAll GendersPhase 3
43 locations